Investor Centre

Living Cell Technologies Ltd (LCT)

LCT:ASX • Healthcare

0.009

UN
CH.

0.00

(0.00)

11:08PM 25/3 (NZST)

VOLUME

169085

52 WEEK RANGE

0.005 - 0.018

1 YR RETURN

-100

Key Information

MARKET CAPITALISATION

$12624120

Novel therapies for serious diseases

LCT is an Australasian biotechnology company improving the wellbeing of people with serious diseases by discovering, developing and commercialising novel treatments for debilitating conditions such as Parkinson’s disease, obesity and migraine.

Our product candidates leverage the potential of cells and their receptors to address serious conditions that have an unmet need for effective treatments.

We are listed on both the Australian Securities Exchange (ASX:LCT) and the international OTCQB (LVCLY). Share registry services are provided by Automic.

Investor Highlights

1 February 2022

NZ pigs possible key to treating Parkinson's

25 January 2022

"Why pigs on this remote Auckland island may be the key to treating Parkinson’s disease" - The Sentiment

"Of all the places in the world where you thought a cure for Parkinson’s disease might be found, the remote sub-Antar...